NanoMedSyn innovates for a better targeting of different therapies related to rare diseases or widespread pathologies such as cancers. NanoMedSyn develops its proprietary patented synthetic derivatives named AMFA (analogues of mannose 6-phosphate) allowing a potent targeting of the cation-independent mannose 6-phosphate receptor (CI-M6PR) which is a key receptor for the treatment of lysosomal diseases or specific cancers.
Firstly, AMFA increase the lysosomal delivery of enzyme replacement therapy (ERT) in the case of lysosomal diseases. AMFA grafting to recombinant enzymes was found to favor lysosomal uptake of enzyme and the therapeutic potential.
Secondly, AMFA allows therapeutic addressing to some cancer types overexpressing the CI-M6PR such as prostate cancer and rhabdomyosarcoma.